Comparison Among Potassium Binders on the Management of Hyperkalemia on Chronic Dialysis Patients: A Protocol for Systematic Review.

Q4 Medicine
Veronica Maressa, Alessandra Farina, Valeria Cernaro, Guido Gembillo, Elisa Longhitano, Giovanni Taverna, Domenico Santoro, Vincenzo Calabrese
{"title":"Comparison Among Potassium Binders on the Management of Hyperkalemia on Chronic Dialysis Patients: A Protocol for Systematic Review.","authors":"Veronica Maressa, Alessandra Farina, Valeria Cernaro, Guido Gembillo, Elisa Longhitano, Giovanni Taverna, Domenico Santoro, Vincenzo Calabrese","doi":"10.69097/42-01-2025-02","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction.</b> Treating hyperkalemia is one of the main goals of supportive care in patients on hemodialysis. In this context, therapy with new potassium binders is a promising resource. <b>Objective.</b> The main aim is to evaluate the difference in serum potassium concentration after treatment with sodium zirconium cyclosilicate or patiromer compared to placebo/sodium polystyrene sulfonate/calcium polystyrene sulfonate. <b>Methods.</b> We will perform systematic research in PubMed, EMBASE, CINAHLE, and grey literature will be screened. We will screen RCTs on patients treated with SZC or patiromer in chronic hemodialysis, without sex or age restriction, which include the differences in serum potassium concentration, adverse events (AEs), and mortality as outcomes. <b>Expected results.</b> This systematic review is expected to provide a comprehensive evaluation of the efficacy and adverse effects of new potassium binders, compared to sodium polystyrene sulfonate or calcium polystyrene sulfonate or placebo, on serum potassium concentration, in a sample of hemodialysis patients. Furthermore, possible gaps in actual knowledge can be highlighted, suggesting new research. <b>Conclusions.</b> The present protocol for a systematic review will consider all existing evidence from published RCTs about the efficacy of HIF-PHIs on hemodialysis patients.</p>","PeriodicalId":12553,"journal":{"name":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","volume":"42 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.69097/42-01-2025-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Treating hyperkalemia is one of the main goals of supportive care in patients on hemodialysis. In this context, therapy with new potassium binders is a promising resource. Objective. The main aim is to evaluate the difference in serum potassium concentration after treatment with sodium zirconium cyclosilicate or patiromer compared to placebo/sodium polystyrene sulfonate/calcium polystyrene sulfonate. Methods. We will perform systematic research in PubMed, EMBASE, CINAHLE, and grey literature will be screened. We will screen RCTs on patients treated with SZC or patiromer in chronic hemodialysis, without sex or age restriction, which include the differences in serum potassium concentration, adverse events (AEs), and mortality as outcomes. Expected results. This systematic review is expected to provide a comprehensive evaluation of the efficacy and adverse effects of new potassium binders, compared to sodium polystyrene sulfonate or calcium polystyrene sulfonate or placebo, on serum potassium concentration, in a sample of hemodialysis patients. Furthermore, possible gaps in actual knowledge can be highlighted, suggesting new research. Conclusions. The present protocol for a systematic review will consider all existing evidence from published RCTs about the efficacy of HIF-PHIs on hemodialysis patients.

比较各种钾结合剂对慢性透析患者高钾血症的治疗效果:系统综述方案
介绍。治疗高钾血症是血液透析患者支持治疗的主要目标之一。在这种情况下,新的钾结合剂治疗是一种很有前途的资源。目标。主要目的是评价与安慰剂/聚苯乙烯磺酸钠/聚苯乙烯磺酸钙相比,环硅酸锆钠或帕特罗默治疗后血清钾浓度的差异。方法。我们将在PubMed, EMBASE, CINAHLE中进行系统研究,筛选灰色文献。我们将筛选在慢性血液透析中接受SZC或patiromer治疗的患者的随机对照试验,没有性别或年龄限制,包括血清钾浓度、不良事件(ae)和死亡率的差异。预期的结果。本系统综述旨在全面评价新型钾结合剂与聚苯乙烯磺酸钠、聚苯乙烯磺酸钙或安慰剂相比,对血液透析患者血清钾浓度的影响。此外,可以突出实际知识中可能存在的差距,从而建议进行新的研究。结论。本系统评价方案将考虑已发表的rct中关于HIF-PHIs对血液透析患者疗效的所有现有证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
62
期刊介绍: Il Giornale Italiano di Nefrologia (GIN) è la rivista di educazione continua della Società Italiana di Nefrologia SIN ed è pubblicato bimestralmente. E" il più autorevole organo di informazione nefrologia disponibile a livello nazionale. Il giornale Italiano di Nefrologia offre la più aggiornata informazione medico-scientifica rivolta al nefrologo sotto forma di rassegne, casi clinici e articoli finalizzati all’Educazione Continua in Medicina, oltre ai notiziari ed agli atti dei congressi di questa prestigiosa Società Scientifica
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信